Stereotaxis (STXS) Non-Current Deffered Revenue (2010 - 2026)
Stereotaxis' (STXS) quarterly Non-Current Deffered Revenue came in at $523000.0 in Q1 2026, down 69.2% year-on-year from $1.7 million in Q1 2025, and down 5.77% on a QoQ basis from $555000.0 in Q4 2025.
Stereotaxis (STXS) Non-Current Deffered Revenue (2010 - 2026) Analysis & Trends
Stereotaxis (STXS) has 17 years of Non-Current Deffered Revenue data on file, last reported at $523000.0 in Q1 2026.
- On a quarterly basis, Non-Current Deffered Revenue fell 69.2% year-over-year to $523000.0 in Q1 2026; TTM through Mar 2026 was $523000.0, a 69.2% decrease from a year earlier, with the FY2025 full-year figure at $555000.0, down 73.11% from the prior year.
- Non-Current Deffered Revenue for Q1 2026 stood at $523000.0, down from $555000.0 in the prior quarter.
- Over the last five years, Non-Current Deffered Revenue for STXS reached as high as $2.1 million in Q2 2024 and fell as low as $523000.0 in Q1 2026.
- Historically, Non-Current Deffered Revenue has averaged $1.5 million across 5 years, with a median of $1.6 million in 2023.
- Across the five-year window, Non-Current Deffered Revenue soared 56.29% in 2022 and sank 73.11% in 2025, its largest moves.
- Year by year, Non-Current Deffered Revenue stood at $1.7 million in 2022, then decreased by 1.03% to $1.6 million in 2023, then advanced by 26.08% to $2.1 million in 2024, then sank by 73.11% to $555000.0 in 2025, then decreased by 5.77% to $523000.0 in 2026.
- Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $523000.0 in Q1 2026, $555000.0 in Q4 2025, and $607000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alcon | 32,734,969.19 Bn | 32,734,967.53 Bn | 1.53 Bn | - |
| 2 | Intuitive Surgical | 117.50 Bn | 112.41 Bn | 1.96 Bn | - |
| 3 | Becton Dickinson | 42.93 Bn | 42.11 Bn | 2.15 Bn | - |
| 4 | Medline | 30.82 Bn | 36.66 Bn | 1.84 Bn | - |
| 5 | Resmed | 27.90 Bn | 26.23 Bn | 890.98 Mn | 163.15 Mn |
| 6 | West Pharmaceutical Services | 26.76 Bn | 26.23 Bn | 329.20 Mn | 13.90 Mn |
| 7 | Cooper Companies | 15.30 Bn | 15.16 Bn | 735.40 Mn | 208.80 Mn |
| 8 | Solventum | 13.46 Bn | 12.90 Bn | 1.10 Bn | - |
| 9 | Align Technology | 12.02 Bn | 10.96 Bn | 736.59 Mn | - |
| 10 | Stereotaxis | 136.49 Mn | 121.87 Mn | 3.79 Mn | 523,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 523,000.00 |
| Dec 31, 2025 | 555,000.00 |
| Sep 30, 2025 | 607,000.00 |
| Jun 30, 2025 | 1.06 Mn |
| Mar 31, 2025 | 1.70 Mn |
| Dec 31, 2024 | 2.06 Mn |
| Sep 30, 2024 | 2.10 Mn |
| Jun 30, 2024 | 2.12 Mn |
| Mar 31, 2024 | 1.58 Mn |
| Dec 31, 2023 | 1.64 Mn |
| Sep 30, 2023 | 1.98 Mn |
| Jun 30, 2023 | 1.64 Mn |
| Mar 31, 2023 | 1.71 Mn |
| Dec 31, 2022 | 1.65 Mn |
| Sep 30, 2022 | 1.42 Mn |
| Jun 30, 2022 | 1.63 Mn |
| Mar 31, 2022 | 2.08 Mn |
| Dec 31, 2021 | 2.24 Mn |
| Sep 30, 2021 | 1.79 Mn |
| Jun 30, 2021 | 1.65 Mn |